Medtronic stock gets FDA clearance for Aristotle Mini Guidewire

Medtronic expanded its neurovascular portfolio on Monday, November 9, after the U.S. Food and Drug Administration cleared the Aristotle Mini Guidewire for use in chronic subdural hematoma treatment. The company described the low-profile access technology as an addition for navigating and treating smaller, more distal neurovascular anatomy.

The announcement was listed in Medtronic's business and regional news. The company said the Aristotle Mini Guidewire complements its Onyx liquid embolic system, linking the new access technology to an existing neurovascular treatment platform.

Portfolio Expansion Adds Neurovascular Capacity

For investors, the clearance broadens the range of tools Medtronic can offer in a specialized part of the neurovascular market. The immediate significance is commercial rather than a reported financial contribution: the announcement did not provide sales guidance, procedure forecasts or a revenue estimate for the product.

The product update also adds a separate growth angle to a news cycle that has recently focused on Medtronic's cardiovascular technologies. Investors will look for evidence of adoption, physician uptake and contribution from newer products in upcoming company disclosures. Those indicators matter because a regulatory clearance can expand commercial opportunity, but does not by itself establish the pace of sales or earnings growth.

Medtronic stock traded at 90.25 euros on Lang & Schwarz at 12:15 CET on Wednesday, November 11, 2026.

The S&P 500 provides the broader US equity-market backdrop for medical-device shares.

More news and analyses on Medtronic stock